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Application of Calculated Panel Reactive Antibody  
Using HLA Frequencies in Koreans
Ji-Young Jang, M.D., Yoon-Joo Kim, M.D., Yonggoo Kim, M.D., Yeon-Joon Park, M.D., Kyungja Han, M.D.,  
and Eun-Jee Oh, M.D.
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Background: Introduction of the Luminex panel reactive antibody (PRA)-single antigen (SA) 
assay has increased the detection rates of unacceptable antigens in sensitized patients; the 
calculated PRA (CPRA) level represents the percentage of actual organ donors that express 
1 or more of these unacceptable antigens. We developed a CPRA calculator based on the 
HLA frequencies in Koreans to measure sensitization levels in Korean patients. 
Methods: To develop the calculator, we obtained the HLA-A, HLA-B, and HLA-DR pheno-
types of 1,622 Koreans, and compared these with previously reported frequencies in Kore-
ans. Sera from patients awaiting kidney transplantation were tested for HLA antibodies by 
Luminex PRA-screen, PRA-identification (ID), and PRA-SA assays. The measured %PRA 
from the PRA-screen (N=55) and PRA-ID (N=71) were compared to the %CPRA for the 
unacceptable antigens obtained from PRA-SA. 
Results: Phenotype frequencies used for the CPRA calculator agreed with previously re-
ported data. The concordance rates among the 3 PRA methods for the detection of class I 
and class II antibodies were 76.1-81.8% (kappa, 0.519-0.636) and 72.7-83.6% (0.463-
0.650), respectively. For the detection of broadly sensitized sera (>50% or  >80%), the 
concordance rates were over 80%. In sera with 80-100% CPRA, 91.7% and 94.4% of the 
samples had concordant results (80-100% PRA) in the PRA-screen and PRA-ID assay, re-
spectively. 
Conclusions: Although further clinical studies are required to confirm the benefits of CPRA 
values, adoption of CPRA analysis based on HLA frequencies in Koreans may be useful 
for sensitization measurements and organ-allocation algorithms.
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INTRODUCTION
Sensitized patients waiting for renal allografts that have preformed 
antibodies against donor-specific HLA antigens are at risk of hy-
peracute, accelerated acute antibody-mediated rejection and 
poor graft outcome. Panel reactive antibodies (PRAs) have been 
used to measure the relative degree of sensitization in renal al-
lograft recipients. PRA levels represent the percentage of likely 
cross-match incompatible donors, and are determined by test-
ing recipient sera against cells from a panel of HLA-typed do-
nors or solubilized HLA antigens attached to a solid phase. The 
panels should be representative of the local pools of potential 
organ donors. However, the results of PRA testing can be highly 
variable and inconsistent depending on the panel composition 
and the techniques used for HLA antibody detection [1, 2]. 
  The development of solid phase-based assays that use solu-Jang J-Y, et al.
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bilized HLA antigens has greatly increased the ability to detect 
and identify HLA-specific antibodies [3-5]. In particular, the use 
of recombinant single antigens (SA) in the Luminex assay makes 
it possible to detect HLA-specific antibodies with greater sensi-
tivity and accuracy. Calculated panel reactive antibody (CPRA) 
values are based on the HLA antigens that are listed as unac-
ceptable for renal transplant candidates. The unacceptable HLA 
antigens can be identified by the presence of HLA antibodies in 
the sera of transplant recipients [2]. This assessment can pre-
dict crossmatch-positive donor kidneys (as a virtual crossmatch) 
and has increased the efficiency of organ allocation.
  A kidney allocation process using CPRA has been established 
in the United Network for Organ Sharing (UNOS) and Eurotrans-
plant allocation system. UNOS awards sensitized patients with 
CPRA levels ≥80 an additional point to increase their access to 
potentially compatible donors. Furthermore, the organ procure-
ment network does not offer organs expressing unacceptable 
HLA antigens to recipients who have HLA antibodies against 
those particular antigens. 
  In contrast, the Korean Network for Organ Sharing (KONOS) 
does not administer the PRA or CPRA, and only uses cross-
match results to measure sensitization for the renal allocation 
system. This is probably due to the variability in PRA methods, 
a lack of organized guidelines, and the differences between the 
antigen composition in commercial PRA panels and that in the 
Korean population. Therefore, a more uniform and accountable 
method for measuring sensitization to HLA antigens based on 
Korean HLA phenotypes is needed. In this study, we developed 
a CPRA calculator using the HLA phenotypes of Koreans to rep-
resent the percentage of actual donors expressing unacceptable 
HLA antigens; then, we compared this CPRA approach with the 
traditional PRA approach using Luminex technology.
METHODS
1. CMC-CPRA calculator
We developed a “Catholic Medical Center (CMC)-CPRA calcula-
tor” with Microsoft Excel using HLA phenotypes derived from 
1,662 healthy Korean donors who underwent HLA-A, HLA-B, and 
HLA-DR typing at Seoul St. Mary’s Hospital from May 2005 to 
March 2010 for related or unrelated organ donation. HLA phe-
notypes were determined by a molecular typing method using 
PCR-sequence specific oligonucleotides (Dynal RELI HLA-A, -B, 
and DRB kits; Dynal Biotech LTD, Wirral, UK). The HLA typing 
results were validated whether observed genotype frequencies 
were consistent with Hardy-Weinberg equilibrium. When HLA-
A, HLA-B, or HLA-DR antibodies detected by Luminex PRA-SA 
testing were entered into the CPRA calculator, a CPRA value 
(%CPRA) was automatically determined as the percentage of 
persons with unacceptable antigens (Fig. 1). We compared the 
HLA phenotype frequencies from this CMC-CPRA calculator to 
those in previous reports based on Korean populations [6, 7]. 
The HLA phenotype frequencies used for the CMC-CPRA cal-
culator were also compared to those for the UNOS- and Eu-
rotransplant Reference Laboratory (ETRL)-calculators on the 
websites at http://optn.transplant.hrsa.gov and http://www.etrl.
org/etrlpra, respectively.
2. PRA-SA assay and CPRA calculation
Seventy-one serum specimens obtained from patients on the 
waiting list for kidney transplantation were tested by the PRA-SA 
assay using LIFECODES LSA class I and class II kits (Gen-Probe 
Transplant Diagnostics Inc., Stamford, CT, USA), and HLA class 
I and class II specificities were identified according to the man-
ufacturer’s instructions. SA beads contained over 90 different 
recombinant HLA-A, HLA-B, and HLA-C class I antigens, and 
over 60 recombinant HLA-DRB, HLA-DQB, and HLA-DPB class 
II antigens. A bead was considered positive if 2 or more of the 
adjusted values were above the 1,000 median fluorescence in-
dex (MFI) cutoff on the Luminex 200 platform (Luminex Corp., 
Austin, TX, USA). To determine the CPRA value, the detected 
Fig. 1. CPRA calculator based on the HLA-A, HLA-B, and HLA-DR 
phenotypes of 1,622 Korean donors.
CPRA calculator
HLA
HLA
*A02
*B58
*DR04
total persons
%CPRA
1,206
1,622
74.4
positive persons HLA specificity
A02A11B39B48DR08DR14
A02A11B39B61DR08DR13
A02A33B44B51DR08DR13
A02A24B61B67DR04DR14
A24A33B44B46DR04DR13
A02A24B35B51DR09DR15
A02A31B35B51DR04DR09
A02A30B64B55DR04DR09
A26A33B55B58DR08DR15
A32A33B44B58DR03DR04
A11A26B62B54DR04DR08
A11A-B51B-DR04DR08
A31A33B61B44DR04DR07
A11A30B13B35DR07DR15
A11A29B07B54DR04DR08
A03A33B35B44DR07DR13
A02A30B13B35DR07DR15
This calculator was developed with Microsoft Excel using the HLA-A, HLA-B, and HLA-DR phenotypes of 1,622 
Korean donors. 
For example, if HLA-A02, HLA-B58 and HLA-DR04 antibodies were detected in the serum of transplant candidate, 
the %CPRA was 74.4% since 74.4% of the persons (1,206/1,622) had HLA-A02, HLA-B58, or HLA-DR04 phenotypes.Jang J-Y, et al.
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HLA-A, HLA-B, and HLA-DR antibody specificities were entered 
into the CMC-CPRA calculator. 
3. PRA-screen/PRA-ID assays and PRA measurement
Out of the 71 serum samples, 55 were tested in a PRA screen 
using the LIFECODES LifeScreen Deluxe kit (Gen-Probe Trans-
plant Diagnostics Inc.). Sera with discrepant results in the PRA-
screen and PRA-ID assays were retested after SeraClean treat-
ment to reduce nonspecific reactions. LifeScreen Deluxe is a 
qualitative Luminex assay that contains 6 different Class I CREG- 
and 4 different Class II CREG-enriched beads in addition to 
beads coated with each class I and class II pooled antigen. If at 
least 1 of the 7 class I HLA beads or at least 1 of the 5class II 
HLA beads was positive, the sample was considered positive for 
class I or class II HLA-specific antibodies, respectively. The PRA 
value (%PRA) for the PRA-screen test was calculated by divid-
ing the number of positive bead reactions by the number of 
CREG beads (6 for class I, and 4 for class II). 
  All 71 sera were tested for PRA-ID using LIFECODES Class I 
and Class II ID kits (Gen-Probe Transplant Diagnostics Inc.), 
and the %PRAs for the PRA-ID test were calculated according 
to the manufacturer’s instructions as the percentage of positive 
bead reactions among the 50 class I beads and 42 class II beads. 
To compare these findings with the CPRA values, which com-
bined class I and class II specificities, the greater %PRA for ei-
ther the class I or class II values was selected.
4. Statistical analysis
Each locus was tested for Hardy-Weinberg equilibrium using 
the GENEPOP program, and exact P values were estimated by 
the Markov chain method [8, 9]. Statistical analyses were per-
formed using SPSS version 12.0 (SPSS, Chicago, IL, USA). Chi-
square analysis was used to compare the phenotype frequen-
cies from different studies. Agreement between the CPRA and 
PRA values was assessed according to kappa coefficient (0.001-
0.2 indicates slight concurrence, 0.201-0.4 indicates fair agree-
ment, 0.401-0.6 shows moderate agreement, 0.601-0.8 indicates 
substantial concurrence, and 0.801-0.999 shows excellent 
agreement). 
RESULTS
1. Phenotype frequencies used for CMC-CPRA calculator
In the CMC-CPRA calculator, the genotype frequencies for the 
HLA-A, HLA-B, and HLA-DR loci were in Hardy-Weinberg equi-
librium (P=0.825, 0.477, and 0.557, respectively). When we 
compared the phenotype frequencies used for the CMC-CPRA 
calculator with those obtained from 2 studies of Korean popula-
tions [6, 7], the B35, B62, and DR15 antigens had greater than 
a 2 percent difference compared to both of the previous studies 
(Table 1). Several antigens, including A11, B35, B44, B46, B56, 
B62, B63, B75, DR11, DR12, DR15, and DR16 differed signifi-
cantly from either one or both of previous data (P<0.05). When 
we compared the phenotype frequencies from the CMC-, UNOS-, 
and ETRL-CPRA calculators, the frequencies of 11 antigens 
(A24, A33, B46, B54, B58, B61, DR4, DR8, DR9, DR12, and 
DR14) were much higher (>10% difference) in the CMC-CPRA 
calculator than in the UNOS- or ETRL-CPRA calculators. The 
frequencies of 6 antigens (A1, A3, B7, B8, DR3, and DR11) in 
the CMC-CPRA calculator were much lower (>10% difference) 
than those in the UNOS- or ETLR-CPRA calculators.
2.     Agreement in the detection of HLA antibodies among the 
Luminex PRA methods 
Agreement between the PRA-screen, PRA-ID, and PRA-SA 
tests when the results represent either the presence or absence 
of HLA antibodies is shown in Table 2. For the detection of class 
I HLA-specific antibodies, the PRA-screen had 80.0% and 81.8% 
agreement with the PRA-ID and PRA-SA methods, respectively. 
The PRA-ID and PRA-SA tests had moderate agreement (76.1%; 
kappa coefficient, 0.519) for the detection of class I HLA-specific 
antibodies. For the detection of class II antibodies, the PRA-
screen test had moderate agreement (72.7%; kappa coefficient, 
0.463) with the PRA-ID due to low co-negativity (58.6%). When 
the results were represented as either positive or negative with 
an 80% cut-off, the PRA-SA tests had 83.6% (0.618) and 81.7% 
(0.597) agreement with the PRA-screen and PRA-ID, respec-
tively. With a 50% cut-off for the detection of highly sensitized 
sera, the assays had 81.8% (0.631) (PRA-screen vs. PRA-SA) 
and 83.1% (0.663) (PRA-ID vs. PRA-SA) agreement. 
3. Comparison of the CPRA and PRA distribution
We compared the PRA values from the PRA-screen and PRA-
ID tests to the CPRA values calculated from the PRA-SA result 
using CMC-PRA calculator. Fig. 2 shows the distribution of PRA 
results within the 5 groups of CPRA levels. In the 80-100% CPRA 
group, the PRA values from the PRA-screen and PRA-ID had 
91.7% and 94.4% agreement with the CPRA values, respec-
tively. However, in the groups with 0%, 1-20%, 21-50%, or 51-
80% CPRA, the concordance rates were less than 80%. There 
were a considerable number of cases with higher %PRA than 
%CPRA in the lower CPRA groups.Jang J-Y, et al.
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DISCUSSION
The use of CPRA is rapidly being adopted by transplant labora-
tories worldwide. The UNOS established a CPRA calculator us-
ing HLA-A, HLA-B, HLA-DR, and HLA-DQ frequencies derived 
from the phenotypes of more than 12,000 donors recently en-
tered into the OPTN registry [10]. The ETRL-CPRA program uses 
HLA typing data from about 4,000 organ donors, including 1,000 
donors from different participating countries. The ETRL-CPRA 
calculation includes the frequencies of HLA-A, HLA-B, HLA-C, 
HLA-DR, and HLA-DQ.
  In clinical laboratories in Korea, the use of PRA tests with a 
solid phase assay is increasing. Additionally, PRA-SA tests have 
recently been introduced in a few laboratories. Therefore, virtual 
crossmatch prediction by CPRA using unacceptable antigens 
could be used to increase the kidney allocation efficiency for 
sensitized patients awaiting transplantation. 
  To obtain the CPRA, a list of unacceptable antigens is required 
instead of a PRA value. In this study, we developed a CMC cal-
culator based on the HLA-A, HLA-B, and HLA-DR frequencies 
derived from the phenotypes of 1,662 Korean donors. The CPRA 
represents the percentage of potential donors who have 1 or 
more unacceptable HLA-A, HLA-B, or HLA-DR antigens. Al-
though the pool of HLA phenotypes for the CMC-CPRA calcula-
tor was much smaller than those for the UNOS or ETRL calcula-
tors, the phenotype data from the CMC-CPRA calculator closely 
corresponded to that obtained in Korean populations. Although 
the phenotype frequencies of several antigens differed signifi-
cantly, the antigens with different frequencies compared to the 
previous data (by 2.1-3.7%) were B35, B62, and DR15. These 
discrepancies might be due to differences in population sam-
pling or the HLA typing methods that were used. Since HLA-A, 
HLA-B, and HLA-DR antigen frequencies differ among various 
populations [11, 12], antigen frequencies in the CMC-CPRA cal-
culator differed from those in the UNOS or ETRL programs. The 
most striking differences were the frequencies of HLA-A1, A3, 
A24, and A33 at the HLA-A locus.
  Traditional PRA tests consist of a panel or pooled antigens, 
including either HLA class I or class II antigens, and represent 
the %PRA. In this study, we used the higher %PRA values 
based on either the class I or class II panel to compare with the 
%CPRA values. Although the PRA values from PRA-screen and 
PRA-ID tests and the CPRA values obtained from PRA-SA test 
varied (Fig. 2), the concordance rates for these were above 80% 
for the detection of broadly sensitized sera (PRA or CPRA levels 
greater than 50% or 80%). In a previous study, concordance 
was generally lower in the lower PRA groups due to an underes-
timation of sensitization using traditional PRA-ID testing [2]. In 
contrast, our study included a considerable number of cases 
that had higher PRA values than the CPRA in the lower CPRA 
groups. This may be due to less agreement for weaker antibod-
Table 2. Concordance rates for the detection of HLA antibodies 
among the Luminex PRA assays using different antigen compositions
Methods N
HLA class I antibodies HLA class II antibodies
Agreement % 
(kappa coefficient)*
Agreement % 
(kappa coefficient)*
PRA-screen vs. PRA-ID 55 80.0 (0.600) 72.7 (0.463)
PRA-screen vs. PRA-SA 55 81.8 (0.636) 83.6 (0.650)
PRA-ID vs. PRA-SA 71 76.1 (0.519) 80.3 (0.601)
*Agreement % (kappa coefficient) between the results (presence or ab-
sence of HLA antibodies) from the PRA-screen, PRA-ID, and PRA-SA tests 
is shown. 
Abbreviations: PRA, panel reactive antibody; ID, identification; SA, single 
antigen.
Fig. 2. Distribution of PRA values (A, by PRA-screen; B, by PRA-ID) for each CPRA group.
*The concordance rate between the PRA and CPRA values for each CPRA group is noted on the bar.
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ies, and additive or synergistic effects of multiple weak antibod-
ies in the PRA-screen and PRA-ID assays. Because weak anti-
bodies may not correlate with a positive flow cytometry cross-
match [13, 14], and appear to have little clinical importance [15-
17], further studies will be necessary to establish the best strat-
egy for predicting strong positive crossmatches [2]. It is also 
possible that the decreased agreement is due to the detection 
of anti-C or anti-DQ antibodies by the PRA-screen and PRA-ID 
tests. The HLA-C, HLA-DQ, and HLA-DP antigens are currently 
excluded from the CMC-CPRA calculation because adequate 
donor typing data to estimate their frequencies were not avail-
able. Since there were several reports indicating that donor-spe-
cific anti-C, anti-DQ, or anti-DP antibodies can induce antibody-
mediated rejection [18-20], these antibodies should be included 
in the CPRA calculators in the future. In addition, allele-specific 
antibodies can be detected by PRA-SA tests, which can lead to 
a positive crossmatch when the target antigen is present in the 
donor. Therefore, it may be important to account for all HLA 
specificities in the CPRA calculator and to test donor HLA typing 
at the allele level, compatible with HLA antibody detection.
  Although PRA and CPRA values had more than 80% agree-
ment for the detection of broadly sensitized sera in this study, 
CPRA values would provide more consistent data for reporting 
sensitization than PRA values. Therefore, in KONOS, CPRA can 
be used to standardize sensitization measurements and can be 
used for standardized allocation of kidneys in an effort to com-
pensate for the biological disadvantage of broadly sensitized pa-
tients. Moreover, high pretransplant PRA values (>50% or 
>80%) are known to be a poor prognostic marker in living do-
nor renal allograft. Therefore, CPRA can also be used as a more 
accurate perioperative immunologic marker, and the adoption 
of virtual crossmatching using unacceptable antigens may in-
crease the number of successful kidney transplantations in sen-
sitized patients [21-23]. 
  In conclusion, the application of unacceptable antigens and 
CPRA based on HLA phenotype frequencies in Koreans may be 
useful for the accurate and consistent measurement of sensiti-
zation and thus promoting efficient kidney allocation. Additional 
clinical studies are needed to confirm the benefit of CPRA cal-
culations for organ allocation and successful transplantation.
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